Dr. Stewart on the Role of Transplant in Multiple Myeloma

Keith Stewart, MB, CHB
Published: Friday, Apr 13, 2018



Keith Stewart, MB, CHB, professor of medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, discusses the role of transplant in patients with multiple myeloma.

Recent clinical trials continue to support the use of transplant over the latest novel therapies. The combination of continuous bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone was compared with the same drugs followed by transplant and some consolidation. Patients who received a transplant had a significant improvement in progression-free survival. No overall survival data were reported due to the short follow-up.

That study was replicated and confirmed by a European study, which suggested that double transplant may be more beneficial than single transplant. That has yet to be confirmed in the United States. The StaMINA clinical trial looked at single and tandem transplant and consolidation chemotherapy in the United States. That study failed to confirm any benefit with a second transplant. In the United States, a single transplant remains the gold standard for patients who are able to undergo that operation, says Stewart.
 


Keith Stewart, MB, CHB, professor of medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, discusses the role of transplant in patients with multiple myeloma.

Recent clinical trials continue to support the use of transplant over the latest novel therapies. The combination of continuous bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone was compared with the same drugs followed by transplant and some consolidation. Patients who received a transplant had a significant improvement in progression-free survival. No overall survival data were reported due to the short follow-up.

That study was replicated and confirmed by a European study, which suggested that double transplant may be more beneficial than single transplant. That has yet to be confirmed in the United States. The StaMINA clinical trial looked at single and tandem transplant and consolidation chemotherapy in the United States. That study failed to confirm any benefit with a second transplant. In the United States, a single transplant remains the gold standard for patients who are able to undergo that operation, says Stewart.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x